An example of AAV-hHDM-FH therapy correcting an inherent deficit in the presence of normal FH levels is noted in the novel mouse model of FHR5 nephropathy (62) while FI has also been successfully delivered to the mouse liver, providing further proof of principal for such approaches (93). Here, FH is linked to kidney disorder.